A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial - PubMed
2 hours ago
- #phase-II-trial
- #esophageal-cancer
- #immunotherapy
- PALADIN is a phase II trial studying induction pembrolizumab + chemotherapy with short-course radiotherapy for unresectable locally advanced esophageal squamous cell carcinoma.
- Treatment includes 4 cycles of pembrolizumab, cisplatin, and 5-fluorouracil, plus 25 Gy radiotherapy in 5 fractions during cycle 1, followed by surgery if eligible.
- Primary endpoint is 2-year overall survival, aiming to improve upon current 15-25% complete response rates and median survival of 13-14 months.
- Planned enrollment is 35 patients, targeting 50% 2-year survival vs. a 30% threshold, with exploratory analysis of circulating tumor DNA.